Share on StockTwits

Inovio Pharmaceuticals (NYSE:INO) Director Morton Collins purchased 8,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, August 21st. The shares were purchased at an average price of $10.01 per share, with a total value of $80,080.00. Following the completion of the transaction, the director now directly owns 173,066 shares of the company’s stock, valued at approximately $1,732,391. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Inovio Pharmaceuticals (NYSE:INO) traded up 1.23% during mid-day trading on Friday, hitting $10.71. 1,358,624 shares of the company’s stock traded hands. Inovio Pharmaceuticals has a 52 week low of $6.40 and a 52 week high of $15.80. The stock’s 50-day moving average is $10.32 and its 200-day moving average is $10.8. The company’s market cap is $646.9 million.

Inovio Pharmaceuticals (NYSE:INO) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. The company had revenue of $3.80 million for the quarter, compared to the consensus estimate of $1.80 million. On average, analysts predict that Inovio Pharmaceuticals will post $-0.63 earnings per share for the current fiscal year.

A number of research firms have recently commented on INO. Analysts at Aegis upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 24th. They now have a $19.00 price target on the stock, up previously from $10.00. Four research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $20.20.

Inovio Pharmaceuticals, Inc is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.